NAMS NEWAMSTERDAM PHARMA COMPANY revenue, earnings and financials
For the quarter ended June 30, 2026, NEWAMSTERDAM PHARMA COMPANY reported revenue of $3.70M (down 80.7% from a year earlier), net income of −$64.1M and diluted EPS of −$0.52; over the last four quarters revenue was $7.12M and net income −$259M; for the fiscal year ended December 2025 revenue was $22.5M, down 50.6% on the year before.
NAMS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $22.5M, gross profit n/a, operating income −$226M, net income −$203M (margin -902.1%), EPS −$1.72
- Fiscal year ended Dec 2024: revenue $45.6M, gross profit n/a, operating income −$176M, net income −$242M (margin -531.1%), EPS −$2.56
- Fiscal year ended Dec 2023: revenue $14.1M, gross profit n/a, operating income −$183M, net income −$177M (margin -1256.2%), EPS −$2.15
- Fiscal year ended Dec 2022: revenue $103M, gross profit n/a, operating income −$3.56M, net income −$22.6M (margin -22.0%), EPS −$1.19
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$35.0M, net income −$41.8M (margin n/a), EPS −$3.81
NAMS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $3.70M (down 80.7% year over year), net income −$64.1M, EPS −$0.52
- Quarter ended Mar 31, 2026: revenue $3.04M (up 2.1% year over year), net income −$48.4M, EPS −$0.40
- Quarter ended Dec 31, 2025 (from the annual report): revenue $32.0K (down 99.7% year over year), net income −$74.1M, EPS −$0.62
- Quarter ended Sep 30, 2025: revenue $348K (down 98.8% year over year), net income −$72.0M, EPS −$0.61
- Quarter ended Jun 30, 2025: revenue $19.1M (up 740.1% year over year), net income −$17.4M, EPS −$0.15
- Quarter ended Mar 31, 2025: revenue $2.98M (up 112.6% year over year), net income −$39.5M, EPS −$0.34
- Quarter ended Dec 31, 2024 (from the annual report): revenue $12.8M (up 1490.5% year over year), net income −$92.6M, EPS −$0.91
- Quarter ended Sep 30, 2024: revenue $29.1M (up 889.8% year over year), net income −$16.6M, EPS −$0.18
- Quarter ended Jun 30, 2024: revenue $2.28M (up 32.7% year over year), net income −$39.0M, EPS −$0.41
- Quarter ended Mar 31, 2024: revenue $1.40M (down 83.8% year over year), net income −$93.8M, EPS −$1.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue $803K, net income −$49.6M, EPS −$0.60
- Quarter ended Sep 30, 2023: revenue $2.94M, net income −$47.1M, EPS −$0.57
- Quarter ended Jun 30, 2023: revenue $1.72M, net income −$38.3M, EPS −$0.47
- Quarter ended Mar 31, 2023: revenue $8.63M, net income −$42.0M, EPS −$0.51
NAMS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$148M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$159M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$141M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $10.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$29.5M, share buybacks n/a
NAMS balance sheet
- Jun 30, 2026: cash $424M, total assets $704M, total liabilities $73.0M, shareholders' equity $631M
- Mar 31, 2026: cash $458M, total assets $733M, total liabilities $67.4M, shareholders' equity $665M
- Dec 31, 2025: cash $490M, total assets $769M, total liabilities $85.9M, shareholders' equity $683M
- Sep 30, 2025: cash $538M, total assets $786M, total liabilities $58.4M, shareholders' equity $728M
- Jun 30, 2025: cash $564M, total assets $815M, total liabilities $36.6M, shareholders' equity $778M
- Mar 31, 2025: cash $748M, total assets $818M, total liabilities $41.1M, shareholders' equity $777M
- Dec 31, 2024: cash $772M, total assets $865M, total liabilities $107M, shareholders' equity $758M
- Sep 30, 2024: cash $423M, total assets $439M, total liabilities $60.3M, shareholders' equity $379M
What is NAMS's revenue?
NEWAMSTERDAM PHARMA COMPANY reported $7.12M of revenue over its last four quarters, through June 30, 2026.
Is NAMS profitable?
No. NEWAMSTERDAM PHARMA COMPANY lost $259M over the last four quarters.
What is NAMS's EPS?
Diluted earnings per share over the last four quarters were −$2.15; −$0.52 in the latest quarter.